title: Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes.
abstract: The field of type 2 diabetes is undergoing a major transformation. Recent cardiovascular outcomes trials of glucose-lowering agents - including EMPA-REG, IRIS and LEADER, have all demonstrated convincing cardiovascular benefits within a relatively short period of time - all likely driven via non-glycemic effects of compounds under study. The implications of these studies (with primary focus on the LEADER trial) - and how their result may be paradigm shifting for type 2 diabetes management, are discussed in this article.
authors.affiliation: Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO. Electronic address: mkosiborod@saint-lukes.org.
authors.forename: Mikhail
authors.initials: M
authors.lastname: Kosiborod
mesh_terms: D002316:Cardiotonic Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000150:complications / Q000453:epidemiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D003925:Diabetic Angiopathies / Q000453:epidemiology / Q000517:prevention & control*; D058065:Diabetic Cardiomyopathies / Q000453:epidemiology / Q000517:prevention & control*; D052216:Glucagon-Like Peptide 1 / Q000819:agonists / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D057285:Precision Medicine; D012307:Risk Factors
chemical_list: D002316:Cardiotonic Agents; D007004:Hypoglycemic Agents; D000960:Hypolipidemic Agents; D052216:Glucagon-Like Peptide 1